ストックスクリーナーアプリを入手
1.72
4.24%
0.07
プレマーケット:
1.73
0.01
+0.58%
前日終値:
$1.65
開ける：
$1.66
24時間の取引高:
1.35M
Relative Volume:
1.16
時価総額：
$73.17M
収益：
-
当期純損益:
$-40.92M
株価収益率:
-1.0019
EPS:
-1.7167
ネットキャッシュフロー:
$-26.53M
1週間 パフォーマンス:
-1.71%
1か月 パフォーマンス:
-16.50%
6か月 パフォーマンス:
-52.22%
1年 パフォーマンス:
-20.74%
1日の値動き範囲:
$1.65
$1.72
1週間の範囲:
$1.645
$1.84
52週間の値動き範囲:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
名前
Annovis Bio Inc
セクター
電話
484-875-3192
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.72 | 73.17M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-10-25 | アップグレード | Maxim Group | Hold → Buy |
| 2023-12-29 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
Annovis Bio Inc (ANVS) 最新ニュース
Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index - marketscreener.com
Annovis Bio | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Annovis Bio | DEFA14A: Others - Moomoo
ANVS Forecast — Price Target — Prediction for 2027 - TradingView
Annovis Bio Inc Actuals & Estimates (FWB:07X) - TradingView
07X Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Price to sales forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Enterprise value to revenue forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Annovis Bio Shareholders Approve Governance and Compensation Changes - The Globe and Mail
Why Annovis’ buntanetap pill is drawing fresh attention in Alzheimer’s race - Ad-hoc-news.de
Annovis Bio Inc (ANVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annovis Bio shareholders approve all proposals at annual meeting By Investing.com - Investing.com Australia
Annovis Bio shareholders approve all proposals at annual meeting - Investing.com UK
Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
Annovis Bio Inc (ANVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Annovis Bio Inc (ANVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annovis Bio Inc (ANVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Press Release: Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants - 富途牛牛
Annovis Bio Inc Stock (US0360431013): Short Interest Climbs At End Of May - AD HOC NEWS
Annovis Bio Price, ANVS Price, Live Charts, and Marketcap - Coinbase
Annovis Regains NYSE Compliance Ahead of Listing Deadline - MyChesCo
Maxim Group Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Annovis Bio (ANVS) Faces Selling Pressure: Key Levels in Focus After 7.6% DeclineVolume Rate Change - thelegaladvocate.com
Annovis Bio regains NYSE listing compliance - MSN
Annovis Bio regains NYSE listing compliance By Investing.com - Investing.com Nigeria
Annovis Bio Regains NYSE Listing Compliance - The Manila Times
Annovis launches proposed public stock and warrant offering - MSN
Annovis Bio Analyst Ratings and Price Targets | NYSE:ANVS - Benzinga
Annovis Bio director Michael Hoffman buys $142,778 in shares By Investing.com - Investing.com Nigeria
Annovis Bio director Michael Hoffman buys $142,778 in shares - Investing.com UK
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Annovis Bio (ANVS) Rebounds 5.39%, Tests Key Resistance After Broader Market Upward MomentumCorrective Wave - thelegaladvocate.com
Director Michael Hoffman adds 76,344 Annovis Bio (ANVS) shares in open-market buys - Stock Titan
Annovis Bio prices $15 million public offering at $1.90 - Investing.com UK
Annovis Bio Announces Dilutive Equity Offering for Trials - TipRanks
Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord Genuity - TradingView
Annovis Bio Inc (ANVS) 財務データ
収益
当期純利益
現金流量
EPS
1.36%
大文字化:
|
ボリューム (24 時間):